Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 18/20 | 0.63 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.56 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15395771 | 0.89 | IL2 (0.65) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL5550559 | 0.87 | IL2 (0.61) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL7932421 | 0.87 | IL2 (0.63) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL17435129 | 0.86 | IL2 (0.62) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL5554240 | 0.84 | IL2 (0.62) | IL2STIM1ORAI1ORAI2 | |
| SCHEMBL15395968 | 0.83 | IL2 (0.59) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL15395847 | 0.83 | IL2 (0.59) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL15395773 | 0.82 | STIM1 (0.57) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL1781322 | 0.82 | IL2 (0.57) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL11911923 | 0.81 | IL2 (0.65) | IL2STIM1ORAI1ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010039238-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | IL2 7/4885STIM1 1054/4885ORAI1 962/4885 |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | IL2 7/4885STIM1 1054/4885ORAI1 962/4885 |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | IL2 7/4885STIM1 1054/4885ORAI1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.